Philadelphia University + Thomas Jefferson University

Jackson, Joseph

< Back



Joseph D. Jackson, PhD, MS

Contact Dr. Jackson

901 Walnut Street
10th Floor
Philadelphia, PA 19107

(215) 503-1074
(215) 923-7583 fax


PhD, University of Mississippi
MS, University of Mississippi
BA, Northern Michigan University


Department of Health Education & Welfare, Health Services Administration and National Institute of Mental Health
Healthcare Administration, National Institute of Mental Health, Saint Elizabeth's Hospital

University Appointments

Adjunct Associate Professor, Jefferson College of Population Health

Research & Practice Interests

Outcomes Research
Patient-Reported Outcomes
Comparative Effectiveness Research


Outcomes & Economic Analysis


Dr. Joseph Jackson has 30 years of experience in the pharmaceutical industry, 25 of which have been spent in clinical research. His work has involved many facets of the management and practice of Outcomes Research, including the translation of clinical evidence into user-friendly cost-effectiveness models concerning parenteral antibiotic therapy (cefotaxime), anticoagulant therapy for stroke prevention (warfarin), lipid management (pravastatin), hypertension management (losartan, irbesartan, omapatrilat), atherothrombosis (clopidogrel) and anticoagulation (apixaban) therapies for cardiovascular event prevention. He has generated Quality of Life evidence, and obtained listing in the package insert for a Patient-Reported Outcomes claim (eflornithine) in the United States and Europe. During his career he has been associated with numerous market access filings in multiple therapeutic areas for Health Technology Assessment reviews, including three Section 114 filings with the Food and Drug Administration (FDA) in the USA and multiple National Institute for Health and Care Excellence (NICE) filings in the United Kingdom. He has served in leadership roles related to outcomes research in the International Society for Pharmacoeconomics and Outcomes Research (ISPOR), Society for Medical Decision Making (SMDM), Pharmaceutical Research and Manufacturers of America (PhRMA) and National Pharmaceutical Council (NPC).

In his current role, Dr. Jackson teaches in the Jefferson College of Population Health's Master of Science in Applied Health Economics & Outcomes Research (MS-AHEOR) program and in the AHEOR specialization in the College's PhD in Population Health Sciences program. These programs ground students in the fundamentals of AHEOR, with emphasis on applications to everyday work settings. Students learn the dimensions of evidence-based value packages to support prudent resource allocation of goods and services in health care. The MS-AHEOR and PhD specialization build on Jefferson's experience and expertise in clinical excellence and aim to provide students with the knowledge of outcomes research, comparative effectiveness and incremental economic value assessments of healthcare interventions.


Most Recent Peer-Reviewed Publications

  1. Venous thromboembolism prophylaxis after total knee or hip replacement: Treatment pattern and outcomes
  2. Economic evaluations alongside effectiveness trials
  3. Long-term cost-effectiveness of clopidogrel in STEMI patients
  4. The risk of cardiovascular events in primary care patients following an episode of severe hypertension
  5. FDAMA 1997 section 114: Another look
  6. Cost-effectiveness of clopidogrel plus aspirin versus aspirin alone for secondary prevention of cardiovascular events: Results from the CHARISMA trial
  7. One-year costs in patients with a history of or at risk for atherothrombosis in the United States
  8. Cost-effectiveness of irbesartan/hydrochlorothiazide in patients with hypertension: An economic evaluation for Sweden
  9. The effect of eflornithine 13.9% cream on the bother and discomfort due to hirsutism
  10. Patient-reported outcome instrument selection: Designing a measurement strategy
  11. Randomized, double-blind clinical evaluation of the efficacy and safety of topical eflornithine HCl 13.9% cream in the treatment of women with facial hair
  12. Multiple co-primary endpoints: Medical and statistical solutions - A report from the Multiple Endpoints Expert Team of the Pharmaceutical Research and Manufacturers of America
  13. Assessing health state utilities in elderly patients at cardiovascular risk
  14. Long-term cost-effectiveness of early and sustained clopidogrel therapy for up to 1 year in patients undergoing percutaneous coronary intervention after presenting with acute coronary syndromes without ST-segment elevation
  15. Long-term cost effectiveness of early and sustained dual oral antiplatelet therapy with clopidogrel given for up to one year after percutaneous coronary intervention: Results from the Clopidogrel for the Reduction of Events During Observation (CREDO) trial
  16. Caring for Hypertension on Initiation: Costs and Effectiveness (CHOICE): A naturalistic design and rationale for the study of patterns of care in hypertension
  17. Allocating funds for cardiovascular disease prevention in light of the NCEP ATP III guidelines
  18. Principles of good practice for decision analytic modeling in health-care evaluation: Report of the ISPOR task force on good research practices - Modeling studies
  19. Measuring the cost-effectiveness of lipid-lowering drugs in the elderly: The outcomes research and economic analysis components of the PROSPER trial
  20. Regulatory issues for health-related quality of life - PhRMA Health Outcomes Committee Workshop, 1999